(Business in Cameroon) - French pharmaceutical company Sanofi released a legal statement on Monday announcing the liquidation of its Cameroonian subsidiary.
Cameroonian Daniel Olinga, who was until now the deputy general administrator of the company (CFA70 million of capital), will lead the liquidation procedure. With this move, Sanofi is materializing its new policy launched in 2021 in several sub-Saharan African countries, including Cameroon, under which the company wants to explore a new business model to "simplify" its presence in certain regions while identifying partners capable of effectively marketing and distributing its portfolio of medicines and vaccines in these areas.
In August last year, Sanofi signed a framework agreement with E.P.DIS (Eurapharma Group) - a leader in the distribution of pharmaceutical products and services in Africa and the French overseas territories. The deal made E.P.DIS Sanofi's exclusive partner for the distribution and marketing of drugs and vaccines in nearly 25 sub-Saharan African countries.
"We are very confident in E.P.DIS's ability to develop Sanofi's product portfolio and to conduct business with a full-service approach while ensuring a smooth and gradual transition. This project changes nothing for the medical community and patients, regarding access to our medicines and vaccines, which will continue to be provided in Cameroon, Côte d'Ivoire, and Senegal regardless of the system that will be put in place," the French group said.
Sanofi started operations in Cameroon in 2006. The multinational company is active in the production and distribution of medicines and vaccines. Its products will now be marketed in the country by the Eurapharma group.
Written by S.A.
Translated from French by Firmine AIZAN